This study has demonstrated the role of the novel fusion gene PLEKHA1-TACC2 in VM formation and its potential as a biomarker for effective ESCC treatment, but it nonetheless has certain limitations. The gene discussed is PLEKHA1; the disease is esophageal squamous cell carcinoma.